← Back to Search

Enzyme Replacement Therapy

Exablate BBBD with Cerezyme for Parkinson's Disease

N/A

Waitlist Available

Research Sponsored by InSightec

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 3 months

Awards & highlights

Study Summary

This trial is testing a new way to deliver a drug to Parkinson's patients using focused ultrasound to open the blood-brain barrier.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Contrast enhancement on MR imaging

Secondary outcome measures

Safety --Adverse events

Other outcome measures

Exploratory effectiveness of Cerezyme delivery via MRgFUS BBB Opening

Exploratory effectiveness of Cerezyme treatment via MRgFUS BBB Opening

Trial Design

1Treatment groups

Experimental Treatment

Group I: Open label single armExperimental Treatment1 Intervention

Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor

88 Previous Clinical Trials

3,700 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease

2020. "Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04370665.

~1 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.